GP Pharm: Injectable Products for the Urology, Oncology, CNS and CVS Fields
GP Pharm, the pharmaceutical company of the Lipotec Group, specialises in the research, development, production...
GP Pharm Concludes Final Reports for Preclinical Studies Of Sarcodoxome®
Final reports for preclinical studies for GP Pharm’s Liposomal Doxorubicine Sarcodoxome® have been released. Those studies are related to one of the major safety improvements of GP Pharm’s formulation and were performed at department of human toxicology, faculty of health, medicine and life sciences.
One of the University of Maastricht’s studies was a comparison of the cardiotoxicity of Liposomal Doxorubicin GP Pharm with free doxorubicin in the mouse using ECG Telemetry Conclusion. Based on the results of this study, it can be conclude that Liposomal doxorubicin GP Pharm is less cardiotoxic than free doxorubicin.
Another study was that of Lipocroman-6, which investigated the activity of a new antioxidant in a LPO (lipid peroxidation) in vitro system. Based on the results of this study, it can be concluded that Lipocroman-6 reduces lipid peroxidation in vitro.
More About This Company
GP Pharm to Exhibit at CPhI 2011
For the eighth consecutive year GP Pharm will be present at CPhI, the world's most...
GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and Irinotecan 300mg and 500mg
GP Pharm has started the commercialisation of Oxaliplatin and Irinotecan 300mg and 500mg, drugs to...
GP Pharm Obtains Approval for GCC Countries
Last January, GCC-DR (Gulf Central Committee for Drug Registration) granted a Registration Certificate of Manufacturing...